|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors attending the conference want to know if companies are planning more M&A in the wake of tax reform. Pricing practices also could be in focus.
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
Incyte (INCY) reported revenues of $384.1 million in its 1Q17 results, which translates to 45.7% revenue growth in 1Q17 as compared to $263.5 million in 1Q16.